Project Grant R01CA310856
Award Date 7/13/26
Completion Date 6/30/31
Dollars Obligated $681K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- Federal Grant Award Summary Beth Israel Deaconess Medical Center, Inc. received a $846,982 Project Grant from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) awarded on August 1, 2025, with an ultimate completion date of July 31, 2032. This seven-year research initiative focuses on understanding the role of innate immunity and epigenetic memory in checkpoint immunotherapy for cancer treatment. The project investigates how the PD-1 (programmed death-1) receptor and...
- Federal Grant Award Summary The National Cancer Institute, under its Cancer Treatment Research program (CFDA 93.395), awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. a Project Grant of $433,256 effective June 1, 2026, with completion targeted for May 31, 2028. This award supports research into fragment-based targeting of epithelial-to-mesenchymal transition (EMT)-mediated resistance in epidermal growth factor receptor (EGFR)-mutant lung cancer. The project leverages...
- Federal Project Grant Award Summary Beth Israel Deaconess Medical Center received a $430,521 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded March 13, 2026, with completion scheduled for February 28, 2029. The award funds development and validation of novel monoclonal antibody tools designed to explore altered glycosylation patterns in tumor cells. The primary deliverables include creation of tumor-associated carbohydrate...
- Federal Project Grant Summary Beth Israel Deaconess Medical Center, Inc. received a $818,625 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective September 1, 2025, through August 31, 2030. The award funds a randomized controlled trial evaluating cardioprotective strategies in newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients with pre-existing cardiomyopathy or prior anthracycline exposure. The primary...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $482,236 to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2025, with a project completion date of July 31, 2030. This investigator-initiated Phase 2 clinical trial will evaluate the safety and efficacy of combining trastuzumab deruxtecan (T-DXD), an antibody-drug conjugate, with the anti-EGFR (epidermal growth factor receptor)...
- Federal Grant Award Summary Beth Israel Deaconess Medical Center, Inc. received a $524,110 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), effective June 1, 2026 through May 31, 2031. The award funds research into one-ended break repair mechanisms in mammalian cells, with particular emphasis on understanding how cells process double-strand breaks (DSBs) and broken replication forks that arise during DNA...
- Federal Grant Award Summary The National Cancer Institute awarded a $736,168 Project Grant to Sloan-Kettering Institute for Cancer Research (award date: August 1, 2025; completion date: July 31, 2030) under the Cancer Treatment Research program (CFDA 93.395) to develop novel antibody-drug conjugates (ADCs) and antibody-oligonucleotide conjugates (AOCs) designed to enhance radiotherapy efficacy through antigen-specific radiosensitization. The research focuses on delivering potent DNA damage...
- Federal Project Grant Award Summary Beth Israel Deaconess Medical Center, Inc. (BIDMC) received a $470,567 Project Grant (R21) award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on July 15, 2025, with an ultimate completion date of June 30, 2027. The award funds research to identify molecular features that predict response or resistance to poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor therapy in metastatic breast cancer patients...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $431,970 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) for the period April 1, 2026, through March 31, 2028. The award supports research to decipher resistance mechanisms to anti-TROP2 antibody-drug conjugates (ADCs), a newly approved class of cancer therapeutics exemplified by sacituzumab govitecan (SG) for treating triple-negative and hormone...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $752,808 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Sloan-Kettering Institute for Cancer Research, effective June 1, 2026 through May 31, 2031. The research project investigates clonal hematopoiesis (CH) as a mechanism of therapeutic resistance in anaplastic thyroid cancer (ATC), with particular focus on how TET2-mutant clonal hematopoietic stem and progenitor cells promote resistance to...